In most cases, we performed all crosses between a given donor by recipient combination, i.e. crosses at all four developmental stages, on the same day.
Given that our transplant model employs the BALB/c (donor)→B6 (recipient) combination, we selected B6×BALB/c (F1) splenocytes as targets, since (i) 2C cells also recognize H2Ld molecules (from BALB/c) (55), and (ii) the presence of "self-MHC molecules" (from B6) prevents killing of the target cells by host's NK cells.
To address this question, we generated bone-marrow chimeric mice using wildtype B6 mice and NMU-KO mice in each possible donor:recipient combination.
Similarly, successful use of MSCs as vehicles for the delivery of therapeutics depends on immunocompatible donor-recipient combinations [26], [27].
In spite of its drawbacks, the CDC-CM has been accepted for years and currently represents the standard procedure for the selection of donor-recipient combinations in order to exclude highly deleterious DSA.
For transplantation, this elaborated technique may result impractical for in situ-delivery of the entire repertoire (or only the immuno-dominant) allo-peptides to recipient's DCs, due to haplotype variability in each donor-recipient combination.
To investigate the effect of DPPIV inhibition on the engraftment of unseparated BM in the absence of alloreactivity, we first used a CD45.2 → CD45.1 congenic donor-recipient combination [36,41].
The beneficial effect of apoptotic cells was donor-specific, took place in different donor and recipient strain combinations, and depended on the biological properties of the apoptotic cells, since i.v. injection of donor splenocytes undergoing primary necrosis (induced by freezing-thawing) did not affect graft survival [ 57, 77].
However, wild type Tau acting as recipient, in combination with either wild-type or mutant Tau seeds as inducer has been demonstrated to be capable of prion-like Tau seeding, albeit much less efficient.
The transplantation risk for each patient was calculated using the European Society for Blood and Marrow Transplantation (EBMT) risk score which includes age at HSCT, disease stage, time from diagnosis to transplantation, donor type and donor recipient sex combination [ 18].
In a restrictive model of bone marrow transplantation in mice, co-administration of apoptotic cells (i.v). the day of the transplant enhanced bone marrow engraftment and prevented GvHD in different donor-recipient strain combinations [ 83].
